

# THE GSK ELLIPTA Inhaler

The ELLIPTA inhaler is designed to be easy to use **with one-step activation**.



**BREO** ELLIPTA  
fluticasone furoate/vilanterol  
**ICS/LABA**



100/25 or 200/25 mcg

BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.

BREO ELLIPTA, an ICS/LABA combination, should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as an ICS, or whose disease severity clearly warrants treatment with both an ICS and a LABA.

BREO ELLIPTA is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist or for patients whose asthma can be successfully managed by ICS along with occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist. BREO ELLIPTA is not indicated for the relief of acute bronchospasm. BREO ELLIPTA 200/25 mcg is not indicated for COPD.

**ARNUITY** ELLIPTA  
fluticasone furoate  
**ICS**



100 or 200 mcg

ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. ARNUITY ELLIPTA is not indicated for the relief of acute bronchospasm.

Please consult the Product Monographs for BREO ELLIPTA and ARNUITY ELLIPTA at [gsk.ca/breo/en](http://gsk.ca/breo/en) and [gsk.ca/arnuity/en](http://gsk.ca/arnuity/en), respectively for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monographs are also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

## THE GSK RESPIRATORY PORTFOLIO

THE ELLIPTA FAMILY OF PRODUCTS



Committed to providing our full line  
of respiratory therapies

gsk



INN OVIVA



MEMBER OF  
INNOVATIVE MEDICINES CANADA

ICS = Inhaled corticosteroid; LABA = Long-acting beta<sub>2</sub>-adrenergic agonist

Trademarks are owned by or licensed to the GSK group of companies.

ANORO ELLIPTA, BREO ELLIPTA, and TRELLEGY ELLIPTA were developed in collaboration with **INN OVIVA**

©2019 GSK group of companies or its licensor.

03360  
07/19

# The GSK COPD portfolio

**INCRUSE** ELLIPTA  
umeclidinium

**LAMA**



62.5 mcg

INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. INCRUSE ELLIPTA is not indicated for the relief of acute deterioration of COPD.

**ANORO** ELLIPTA  
umeclidinium/vilanterol

**LAMA/LABA**



62.5/25 mcg

ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta<sub>2</sub>-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ANORO ELLIPTA is not indicated for the relief of acute deterioration of COPD. ANORO ELLIPTA is not indicated for the treatment of asthma. The safety and efficacy of ANORO ELLIPTA in asthma have not been established.

**BREO** ELLIPTA  
fluticasone furoate/vilanterol

**ICS/LABA**



100/25 mcg

BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD. BREO ELLIPTA 200/25 mcg is not indicated for patients with COPD. There is no additional benefit of the 200/25 mcg dose compared to the 100/25 mcg dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions. BREO ELLIPTA is not indicated for the relief of acute bronchospasm.

**TRELEGY** ELLIPTA  
fluticasone furoate/umeclidinium/vilanterol

**ICS/LAMA/LABA**



100/62.5/25 mcg

TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) 100/62.5/25 mcg is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), indicated in patients who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA:

- For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- To reduce exacerbations of COPD in patients with a history of exacerbations.

TRELEGY ELLIPTA is not indicated for the relief of acute bronchospasm and is not indicated for the treatment of asthma.

Please consult the Product Monographs for INCRUSE ELLIPTA, ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA at [gsk.ca/incruse/en](http://gsk.ca/incruse/en), [gsk.ca/anoro/en](http://gsk.ca/anoro/en), [gsk.ca/breo/en](http://gsk.ca/breo/en), and [gsk.ca/trelegy/pm](http://gsk.ca/trelegy/pm), respectively for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monographs are also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

COPD = Chronic obstructive pulmonary disease; LAMA = Long-acting muscarinic antagonist; ICS = Inhaled corticosteroid; LABA = Long-acting beta<sub>2</sub>-adrenergic agonist